ALLO - Allogene Therapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
247
243
38,489
0
0
Operating expenses
Research development
234,951
256,387
220,176
192,987
144,535
Selling general and administrative
78,264
79,305
74,105
65,256
57,473
Total operating expenses
313,215
335,692
294,281
258,243
202,008
Operating income or loss
-312,968
-335,449
-255,792
-258,243
-202,008
Interest expense
-
-
-
0
0
Total other income/expenses net
-1,680
-1,749
-2,927
-1,142
-268
Income before tax
-312,653
-332,632
-257,005
-250,221
-184,925
Income tax expense
-
-
0
0
-331
Income from continuing operations
-312,653
-332,632
-257,005
-250,221
-184,594
Net income
-312,653
-332,632
-257,005
-250,221
-184,594
Net income available to common shareholders
-312,653
-332,632
-257,005
-250,221
-184,594
Basic EPS
-
-2.32
-1.89
-2.08
-1.83
Diluted EPS
-
-2.32
-1.89
-2.08
-1.83
Basic average shares
-
143,147
135,820
120,370
101,061
Diluted average shares
-
143,147
135,820
120,370
101,061
EBITDA
-
-335,449
-255,792
-258,243
-184,925